TY - JOUR
T1 - Therapeutic outcome of >10 cycles of cabazitaxel for castration-resistant prostate cancer
T2 - A Multi-institutional Study
AU - Shiota, Masaki
AU - Nakamura, Motonobu
AU - Yokomizo, Akira
AU - Tomoda, Toshihisa
AU - Sakamoto, Naotaka
AU - Seki, Narihito
AU - Hasegawa, Shuji
AU - Yunoki, Takakazu
AU - Harano, Masahiko
AU - Kuroiwa, Kentaro
AU - Eto, Masatoshi
N1 - Funding Information:
This work was supported by JSPS KAKENHI grant (17K11145). The Authors would like to acknowledge the contributions of the following collaborators: Akito Yamaguchi at Harasanshin Hospital (Fukuoka), Takashi Dejima at Kyushu Central Hospital (Fukuoka), Satoshi Otsubo at Kitakyushu Municipal Medical Center (Kitakyushu), Akio Tsutsui at JCHO Kyushu Hospital (Kitakyushu), and Yoshifumi Hori at Miyazaki Prefectural Miyazaki Hospital (Miyazaki). The Authors also thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
Publisher Copyright:
© 2019 International Institute of Anticancer Research. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background/Aim: Cabazitaxel use has usually been limited to up to 10 cycles in most countries according to the protocol in the TROPIC trial. Therefore, clinical data on cabazitaxel use beyond 10 cycles is limited. The aim of this study was to report the therapeutic outcome of cabazitaxel chemotherapy administered for >10 cycles. Patients and Methods: This study included 74 Japanese patients with prostate cancer between 2014 and 2017. Patients background, and treatment outcomes including PSA decline, progression-free survival, treatment-failure-free survival, overall survival, and adverse events were investigated, comparing patients treated with ≤10 and >10 cycles. Results: Patients characteristics were favorable as indicated by the higher number of cycles of prior docetaxel chemotherapy, absence of pain, and absence of bony and visceral metastases among men who received >10 cycles of cabazitaxel. PSA response, progression-free survival, treatment-failure-free survival and overall survival were better among patients treated with >10 cycles of cabazitaxel compared to those treated with ≤10 cycles. The incidence of severe adverse events was similar between the two groups. Conclusion: Taken together, this study suggested that continuous chemotherapy with cabazitaxel beyond 10 cycles may be beneficial.
AB - Background/Aim: Cabazitaxel use has usually been limited to up to 10 cycles in most countries according to the protocol in the TROPIC trial. Therefore, clinical data on cabazitaxel use beyond 10 cycles is limited. The aim of this study was to report the therapeutic outcome of cabazitaxel chemotherapy administered for >10 cycles. Patients and Methods: This study included 74 Japanese patients with prostate cancer between 2014 and 2017. Patients background, and treatment outcomes including PSA decline, progression-free survival, treatment-failure-free survival, overall survival, and adverse events were investigated, comparing patients treated with ≤10 and >10 cycles. Results: Patients characteristics were favorable as indicated by the higher number of cycles of prior docetaxel chemotherapy, absence of pain, and absence of bony and visceral metastases among men who received >10 cycles of cabazitaxel. PSA response, progression-free survival, treatment-failure-free survival and overall survival were better among patients treated with >10 cycles of cabazitaxel compared to those treated with ≤10 cycles. The incidence of severe adverse events was similar between the two groups. Conclusion: Taken together, this study suggested that continuous chemotherapy with cabazitaxel beyond 10 cycles may be beneficial.
UR - http://www.scopus.com/inward/record.url?scp=85070719721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070719721&partnerID=8YFLogxK
U2 - 10.21873/anticanres.13612
DO - 10.21873/anticanres.13612
M3 - Article
C2 - 31366538
AN - SCOPUS:85070719721
VL - 39
SP - 4411
EP - 4414
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 8
ER -
